NEW YORK--(BUSINESS WIRE)-- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of PharMerica Corporation ("PharMerica" or the "Company") (NYSE: PMC) in connection with the proposed sale of the Company to Omnicare, Inc. (“Omnicare”) (NYSE: OCR) for approximately $441 million.
On August 23, 2011, it was announced that Omnicare offered to buy PharMerica. PharMerica’s board of directors subsequently rejected the offer. Under Omnicare’s bid, PharMerica shareholders would have received $15.00 per share in cash. Our investigation concerns the board of directors’ process for consideration of the proposed transaction and whether the proposed consideration to be paid to PharMerica shareholders would be fair and adequate.
If you own shares of PharMerica and would like to learn more about these claims or if you wish to discuss this matter and have any questions or information concerning this announcement, please contact Daniella Quitt, Esq. at [email protected] or Benjamin Sachs-Michaels at [email protected]. You may also call them at (877) 935-7400. For more information about class actions, please visit our website: www.hfesq.com.
Harwood Feffer LLP is a national shareholder litigation firm. Harwood Feffer LLP is devoted to protecting the interests of individual and institutional investors in shareholder actions in state and federal courts nationwide.
Attorney Advertising. © 2011 Harwood Feffer LLP. The law firm responsible for this advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.
KEYWORDS: United States North America Kentucky New York
INDUSTRY KEYWORDS: Practice Management Health Hospitals Pharmaceutical Professional Services Finance Legal Managed Care